Press Releases
Aug 1, 2022

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022. 1. Top...

Jul 26, 2022

– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash., July 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa,...

Jul 21, 2022

New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate and program areas TOKYO and SAN FRANCISCO,...

EXPLORE ALL US PRESS RELEASES

Articles
Jul 20, 2022

Our consistent score of 100 recognizes our continuing effort to create an inclusive culture for people with disabilities. For the third year in a row, Astellas has been included in the Disability...

Jul 14, 2022

Astellas Pharma US President Mark Reisenauer recently joined PhRMA Senior Vice President of State Advocacy Scott LaGanga for a conversation about a range of topics that are important to patients...

Jun 14, 2022

Great Place to Work and Fortune magazine have honored Astellas as one of this year’s Best Workplaces in Chicago. Astellas, ranked #X, is among the best companies to work for headquartered in...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products